Nuo Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
AURXStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Nuo Therapeutics, Inc.
Consolidated Statements of Cash Flows
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(2,512,216) | $(2,323,705) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 85,463 | 23,022 |
| Stock-based compensation | 85,986 | 56,652 |
| Provision for credit losses | 91,401 | 79,445 |
| Provision for inventory obsolescence | 19,371 | 30,000 |
| Vendor expense settled in shares of common stock | 51,000 | - |
| Gain on settlement of accounts payable | - | (133,623) |
| Amortization of operating lease right of use assets | 71,476 | 73,247 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (404,863) | (76,947) |
| Inventory, net | (82,690) | 29,147 |
| Prepaid expenses and other current assets | 103,676 | 15,286 |
| Accounts payable | 216,893 | (41,706) |
| Accrued liabilities | 201,392 | 103,778 |
| Deferred revenue | 1,275,000 | - |
| Operating lease liabilities | (66,860) | (66,218) |
| Net cash used in operating activities | (864,971) | (2,231,622) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchases of property and equipment | (274,756) | (154,962) |
| Net cash used in investing activities | (274,756) | (154,962) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Net proceeds from issuance of common stock | 791,418 | 1,500,000 |
| Net proceeds from option exercises | 113,541 | 90,417 |
| Net proceeds from note payable issuance | 300,000 | - |
| Net proceeds from note payable issuance – related party | 200,000 | - |
| Net proceeds from warrant exercise | - | 151,200 |
| Net cash provided by financing activities | 1,404,959 | 1,741,617 |
| NET INCREASE (DECREASE) IN CASH | 265,232 | (644,967) |
| Cash, beginning of period | 283,714 | 928,681 |
| Cash, end of period | $548,946 | $283,714 |
| SUPPLEMENTAL INFORMATION | ||
| Cash paid during the period for: | ||
| Interest | $4,721 | $4,494 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.